Collateral activity of the CRISPR/RfxCas13d system in human cells

Peiguo Shi(Columbia University Irving Medical Center), Michael R. Murphy(Columbia University Irving Medical Center), Alexis O. Aparicio(Columbia University Irving Medical Center), Jordan S. Kesner(Columbia University Irving Medical Center), Zhou Fang(Columbia University Irving Medical Center), Ziheng Chen(Columbia University Irving Medical Center), Aditi Trehan(Columbia University Irving Medical Center), Yang Guo(Columbia University Irving Medical Center), Xuebing Wu(Columbia University Irving Medical Center)
Communications Biology
March 28, 2023
Cited by 80Open Access
Full Text

Abstract

CRISPR/Cas13 systems are increasingly used for programmable targeting of RNAs. While Cas13 nucleases are capable of degrading both target RNAs and bystander RNAs in vitro and in bacteria, initial studies fail to detect collateral degradation of non-target RNAs in eukaryotic cells. Here we show that RfxCas13d, also known as CasRx, a widely used Cas13 system, can cause collateral transcriptome destruction when targeting abundant reporter RNA and endogenous RNAs, resulting in proliferation defect in target cells. While these results call for caution of using RfxCas13d for targeted RNA knockdown, we demonstrated that the collateral activity can be harnessed for selective depletion of a specific cell population defined by a marker RNA in an in vitro setting.


Related Papers

No related papers found

Powered by citation graph analysis